NEW YORK (GenomeWeb News) – Medical & Biological Laboratories today announced it has signed a non-exclusive agreement with Envoy Therapeutics to provide it access to MBL's RIP-Chip technology.
Under the terms of the deal, MBL will receive an upfront payment of an undisclosed amount, annual licensing fees and potential milestone payments. Envoy will use the RIP-Chip for drug discovery and development.
Further terms of the deal were not disclosed.
MBL's RIP-Chip is for RNA-binding protein immunoprecipitation for microarray, sequencing, and PCR applications, according to the company's website. The technology is the only high-throughput approach for direct elucidation of complex molecular networks involving genes, DNA, RNA, microRNA, proteins, and RNA localization as mediated by specific binding proteins.
The importance of such networks has become increasingly evident with "the growing appreciation of RNAi therapy, drug discovery, and the role of RNA utilization in determining normal and disease outcomes," MBL said in a statement
MBL is based in Nagoya, Japan and develops solutions and clinical diagnostics. Envoy, headquartered in Jupiter, Fla., develops therapeutics with technology that combines genetic engineering with new molecular biology methods for labeling and extracting protein-making components of specific cell types.